Canaccord analyst Whitney Ijem lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $36 from $39 and keeps a Buy rating on the shares. The firm said the 4Q24 earnings report was uneventful, with pipeline updates largely on track where the focus remains on the Danon program’s upcoming update expected in 1H25.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Promising Pipeline and Financial Stability Drive Buy Rating for Rocket Pharmaceuticals
- Rocket Pharmaceuticals Advances Gene Therapy Pipeline
- Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs
- Rocket Pharmaceuticals price target lowered to $54 from $62 at Chardan
- Promising Outlook for Rocket Pharmaceuticals: Buy Rating Reiterated with $32 Price Target